Search

everythinglearnresearchcommunity

for

Search:↓

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

The user experienced significant hair improvement using finasteride, minoxidil, ketoconazole shampoo, and microneedling over a year, with no side effects. They used topical minoxidil and reported shedding phases, but no current shedding as of March 2026.

The user shared their hair loss treatment progress using Finasteride, Dutasteride, and Minoxidil, noting initial irritation with topical Minoxidil and experiencing shedding phases. They reported no side effects and encouraged others to try this regimen for alopecia.

Switching from topical to oral minoxidil and dutasteride led to severe hair thinning and shedding, with no side effects. The user is unsure if this is a temporary shedding phase or if oral minoxidil is less effective.

The conversation discusses hair shedding experienced by users on minoxidil and finasteride treatments, with some considering additional options like spironolactone and dutasteride. Many users report experiencing a second shedding phase but are advised to continue treatment as it may lead to thicker hair regrowth.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

A 28-year-old male is experiencing temple regrowth but crown thinning while using 5mg minoxidil and 0.5mg dutasteride. The shedding phase is seen as a positive sign of treatment effectiveness, with expectations of noticeable improvements around 6 to 12 months.

OP used 0.4 mg Dutasteride and 2 mg Minoxidil for 7 months, seeing significant hair density improvement without a noticeable shedding phase. OP takes a combined oral pill from Musely and is in their early forties.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The conversation discusses hair loss treatments, specifically the transition from topical to oral minoxidil and finasteride, and the associated shedding phase. Users advise patience and consistency, noting that shedding is common and improvement may take several months.

Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

A user experienced no visible improvement in hair loss after 10 months on 0.5mg finasteride and increased the dose to 1mg, noticing a possible shedding phase. They also use topical minoxidil, ketoconazole shampoo, and dermastamping, and are seeking others' experiences with similar treatments.

A user successfully regrew hair using 1mg finasteride, switching to 0.5mg dutasteride, and maintaining 5mg oral minoxidil, with significant improvements noted after switching to dutasteride. The user experienced shedding phases but ultimately achieved regrowth and is now comfortable without wearing a hat.

A 19-year-old is experiencing crown thinning after three months on finasteride and minoxidil, hoping it's just a shedding phase. They also use a dermaroller weekly and seek hair regrowth and stabilization.

The user has been using finasteride for 16 months, minoxidil for 11 months, and started microneedling 2 months ago, experiencing shedding phases. They are questioning whether they are experiencing miniaturization or regrowth.

An 18-year-old male using minoxidil and finasteride is experiencing increased hair loss, possibly due to a shedding phase from finasteride. He also takes zinc, magnesium, calcium, and vitamin C, and is concerned about hair loss from his temples.

The user shared progress pictures showing hair regrowth over 7 months using topical Minoxidil, topical Finasteride, and multivitamins with biotin, noting more regrowth at 3 months than at 7 months. They suspect a shedding phase and are considering the impact of not continuing microneedling.

The user experienced significant hair regrowth after 10 months of using Minoxidil and 8 months of Finasteride, despite an initial shedding phase. They reported minor initial side effects but overall positive results, with the crown area completely filled in.

The user experienced initial regrowth with finasteride and minoxidil but is now facing increased hair thinning, possibly due to a second shedding phase. They are considering increasing finasteride dosage or adding dutasteride, despite availability issues, and have started microneedling.

A user shared their experience with hair loss treatments, switching from 1mg finasteride and topical minoxidil to 5mg oral minoxidil and oral dutasteride, noting improvements despite shedding phases. Other users discussed the hair growth cycle, treatment effects, and shared advice on managing hair loss, including buzzing hair and maintaining mental health.

After 3 months of using oral minoxidil and finasteride, the user experienced thicker hair and filled-in thinning areas, with no major side effects except an initial shedding phase. The treatments were prescribed online, and the user noticed results after 2.5 months.

The user experienced hair regrowth using a topical solution containing 5% minoxidil and 0.1% finasteride, despite an initial shedding phase. They reported no side effects and noted significant improvement in hair density, particularly around the crown area.

The user started using Dutasteride 0.5mg, Minoxidil 2.5mg, and Biotin 10mg for hair loss. They are experiencing increased hair thinning, likely due to the shedding phase.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The user experienced hair regrowth after 5 months on 5 mg oral minoxidil and 1 mg dutasteride, following a year of ineffective finasteride use. They noticed progress after an initial shedding phase and hope for further improvement, with expectations of near-max regrowth around 18 months.

The user had a hair transplant in December 2024 and started using topical minoxidil and finasteride in March 2025, along with dermarolling and multivitamins. They are experiencing increased hair shedding and are questioning if it's the "dread shed" phase.